Kiyatec's 3D Predict Glioma Test Improves Patient Survival
Kiyatec's 3D Predict Glioma Test Improves Patient Survival Rates
Kiyatec, a developer of predictive diagnostics, has unveiled data suggesting that its 3D Predict Glioma test substantially boosts survival outcomes for individuals with high-grade glioma (HGG) by precisely forecasting their reaction to chemotherapy. In a report featured in Scientific Reports, the research indicated that patients who positively responded to the test encountered a median progression-free survival increase of 5.8 months and an overall survival increase of 7.6 months compared to those who did not respond. The testing process entails implanting cancer cells into a 3D cell culture, which is then subjected to radiation and temozolomide – the prevailing treatment for HGG. Eric Perreault, Kiyatec's CEO, emphasized the significance of this achievement in advancing tailored treatment options for HGG patients. Notably, Kiyatec previously collaborated with AstraZeneca to evaluate preclinical assets using their KIYA-Predict platform and secured $18 million in Series C funding led by Bruker in 2022.
Key Takeaways
- Kiyatec's 3D Predict Glioma test enhances survival in high-grade glioma patients by predicting chemotherapy response.
- Tested patients showed a 5.8-month increase in progression-free survival and 7.6 months in overall survival.
- The test uses 3D cell cultures to mimic natural human cell interactions, treated with standard HGG therapy.
- Non-responsive HGG patients may be directed to clinical trials for potentially better treatment options.
- Kiyatec partnered with AstraZeneca in 2023 to evaluate preclinical assets using their KIYA-Predict platform.
Analysis
Kiyatec's significant progress in predictive diagnostics for high-grade glioma patients could revolutionize treatment protocols, benefitting patients and healthcare systems by enhancing survival rates and reducing ineffective treatments. The partnership with AstraZeneca and prior funding from Bruker positions Kiyatec well for market expansion and further research and development. In the short-term, this technology elevates Kiyatec's reputation and investor confidence. In the long run, it could lead to wider adoption of personalized medicine in oncology, influencing pharmaceutical research and clinical trial design.
Did You Know?
- 3D Predict Glioma Test:
- The 3D Predict Glioma test developed by Kiyatec is a diagnostic tool designed to predict how patients with high-grade glioma (HGG) will respond to chemotherapy. This test uses a 3D cell culture model, which more accurately mimics the natural environment of human cells compared to traditional 2D cultures. By exposing these 3D cultures to standard treatments like radiation and temozolomide, the test can predict patient responses, thereby guiding more effective treatment plans.
- High-Grade Glioma (HGG):
- High-grade glioma is a type of brain tumor that is characterized by its aggressive nature and rapid growth. These tumors are typically classified as grade III or IV by the World Health Organization, indicating a high degree of malignancy. Treatment for HGG often includes surgery, radiation, and chemotherapy, but outcomes can vary widely due to the tumor's resistance to treatment and its location in the brain.
- Median Progression-Free Survival and Overall Survival:
- These terms are key metrics used in clinical studies to measure the effectiveness of treatments for cancer. Median progression-free survival refers to the length of time during and after treatment during which patients live with the disease but it does not get worse. Overall survival is the length of time from either diagnosis or treatment during which patients with a disease are still alive. In the context of Kiyatec's study, these metrics showed significant improvements for patients whose responses were accurately predicted by the 3D Predict Glioma test.